Cingulate Inc. (CING) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cingulate Inc., a Delaware corporation, on January 7, 2025. The company is an emerging growth company with its principal executive offices in Kansas City, KS. The report discloses material developments regarding its lead drug candidate, CTx-1301 (dexmethylphenidate), intended for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on clinical development milestones and regulatory updates.
Material Changes and Developments
- Study Completion: The Company completed its final FDA-required study, a food effect study, for CTx-1301.
- Safety Profile: No serious adverse events were reported during the study.
- Regulatory Timeline: A New Drug Application (NDA) submission to the FDA is targeted for mid-2025.
Outlook, Guidance, and Management Commentary
Management expects a data readout regarding bioavailability with or without food in the second quarter of 2025. The successful completion of this study positions the company to proceed with its planned NDA submission. The press release associated with this filing is furnished as Exhibit 99.1 but is not deemed "filed" for liability purposes under the Exchange Act.
Investor Verification Checklist
- Verify the specific bioavailability data readout when released in Q2 2025.
- Monitor the official FDA acceptance of the NDA submission targeted for mid-2025.
- Review the full text of the press release (Exhibit 99.1) for detailed study parameters.
- Check subsequent filings for any updates on the Company's cash position and funding requirements to support the NDA process.